Please provide your email address to receive an email when new articles are posted on . Semaglutide is approved by the FDA for slowing the progression of chronic kidney disease. Liraglutide and ...
Morning Overview on MSN
Review finds GLP-1 weight-loss drugs may cut Alzheimer’s amyloid and tau
Drugs best known for helping people lose weight may also chip away at the proteins that define Alzheimer’s disease. A ...
Risks for kidney failure and major cardiovascular events between three GLP-1 receptor agonists were similar among veterans with diabetes. Mortality risk and certain adverse events differed between the ...
About The Study: In this comparative effectiveness study in veterans with diabetes, liraglutide, semaglutide, and dulaglutide initiators had similar risks for kidney and cardiovascular outcomes.
Here’s what researchers want you to know.
Can weight-loss drugs like semaglutide prevent Alzheimer's? New research reveals GLP-1 drugs reduce amyloid and tau proteins ...
Exposure to semaglutide and liraglutide, especially during first 6 months of treatment, was associated with new-onset rheumatoid arthritis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results